Drugs / Pluripotent Adipose-Derived Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06141317 | Jun 2023 → Sep 2024 | Parkinson disease | ClusterXStem-Costa Rica | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pluripotent Adipose-Derived Stem Cells | “Pluripotent Adipose-Derived Stem Cells (PASCs) will be delivered intravenously at a dosage of 25 million PASCs/patient to Parkinson's Disease patients for three infusions each...” NCT06141317 ↗ |
| Known as | PASCs | “Pluripotent Adipose-Derived Stem Cells (PASCs) will be delivered intravenously at a dosage of 25 million PASCs/patient to Parkinson's Disease patients for three infusions each...” NCT06141317 ↗ |
| Modality | Cell therapy | “Pluripotent Adipose-Derived Stem Cells (PASCs)” NCT06141317 ↗ |
| Route | Intravenous | “will be delivered intravenously” NCT06141317 ↗ |